Antibody maturation in women who acquire HIV infection while using antiretroviral preexposure prophylaxis

Journal of Infectious Diseases

Volumn 212, Issue 5, 2015, Pages 754-759

  Laeyendecker, Oliver ^a   Redd, Andrew D ^a   Nason, Martha ^b   Longosz, Andrew F ^a   Karim, Quarraisha Abdool ^f   Naranbhai, Vivek ^f   Garrett, Nigel ^f   Eshleman, Susan H ^a   Abdool Karim, Salim S ^c,d,e,f   Quinn, Thomas C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e Ragon Institute   (United States)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Antibody maturation; HIV; Incidence assay; Preexposure prophylaxis

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PLACEBO; TENOFOVIR; ADENINE; ANTIRETROVIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

ADULT; ANALYTICAL EQUIPMENT; ANTIBODY MATURATION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; BED CAPTURE ENZYME IMMUNOASSAY; BIO PLEX ASSAY; BIO RAD AVIDITY ASSAY; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; SEROLOGY; ANALOGS AND DERIVATIVES; ANTIBODY AFFINITY; BLOOD; COHORT ANALYSIS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOASSAY; IMMUNOLOGY; TIME; YOUNG ADULT;

ADENINE; ADULT; ANTI-RETROVIRAL AGENTS; ANTIBODY AFFINITY; COHORT STUDIES; FEMALE; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNOASSAY; ORGANOPHOSPHONATES; PRE-EXPOSURE PROPHYLAXIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TENOFOVIR; TIME FACTORS; YOUNG ADULT;

EID: 84943327425     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv110     Document Type: Article

References (19)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-74.
2. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-34.
3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
4. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012; 26:F13-9.
5. Killian MS, Norris PJ, Rawal BD, et al. The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response. AIDS Res Hum Retroviruses 2006; 22:640-7.
6. Curtis KA, Kennedy MS, Luckay A, et al. Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis. J Acquir Immune Defic Syndr 2011; 57:355-62.
7. van Loggerenberg F, Mlisana K, Williamson C, et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One 2008; 3: e1954.
8. Dobbs T, Kennedy S, Pau CP, McDougal JS, Parekh BS. Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol 2004; 42:2623-8.
9. Curtis KA, Kennedy MS, Charurat M, et al. Development and characterization of a bead-based, multiplex assay for estimation of recent HIV type 1 infection. AIDS Res Hum Retroviruses 2012; 28:188-97.
10. Masciotra S, Dobbs T, Candal D, et al. Antibody avidity-based assay for identifying recent HIV-1 infections based on genetic systems TM1 / 2 plus O EIA [abstract 937]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 16-19 February 2010.
11. van Loggerenberg F, Mlisana K, Williamson C, et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One 2008; 16: e1954.
12. Garrett NJ, Werner L, Naicker N, et al. HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel preexposure prophylaxis trial. J Acquir Immune Defic Syndr 2015; 68:55-61.
13. Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005; 40: 868-73.
14. Marinda ET, Hargrove J, PreiserW, et al. Significantly diminished longterm specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 53:496-9.
15. Wendel SK, Mullis CE, Eshleman SH, et al. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection. PLoS One 2013; 8:e55525.
16. Cimerman S, Sucupira MC, Lewi DS, Diaz RS. Less sensitive HIV-1 enzyme immunoassay as an adjuvant method for monitoring patients receiving antiretroviral therapy. AIDS Patient Care STDS 2007; 21: 100-5.
17. Longosz AF, Mehta SH, Kirk GD, et al. Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. AIDS 2014; 28:1227-32.
18. Keating SM, Hanson D, Lebedeva M, et al. Lower-sensitivity and avidity modifications of the vitros anti-HIV 1+2 assay for detection of recent HIV infections and incidence estimation. J Clin Microbiol 2012; 50:3968-76.
19. Valley-Omar Z, Sibeko S, Anderson J, et al. CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck. J Infect Dis 2012; 206:35-40.